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ABSTRACT 
Background: Hepatocarcinoma (HCC) is the fifth most commonly diagnosed cancer 
and the second cause of cancer death in men worldwide, while in women represents the 
seventh most frequently diagnosed cancer and the sixth leading cause of cancer related 
death. HCC incidence is 10-20/100.000 per year and its mortality rate is 16/100.000 per 
year. 70-90% of patients are affected by liver cirrhosis and indeed this represents the 
greatest risk factor for HCC. Worldwide almost 54% of HCC is attributable to HBV 
infections, while 30% are caused by HCV and 15% by alcohol consumption. During 
progression from chronic liver disease to cirrhosis and then HCC, inflammation plays a 
pivotal role through changes in the hepatic microenvironment. Key factors are the 
cytokines IL-6 and Tumour Necrosis Factor α (TNF), and the adhesion proteins 
Vascular Adhesion Protein 1 (VAP-1), Intercellular Adhesion Molecule 1 (ICAM-1) 
and Vascular Cell Adhesion Molecule (VCAM-1). 
Aims: The main aim of the study is to evaluate IL-6, TNF, VAP-1, ICAM-1 and 
VCAM-1 expression in serum samples of cirrhotic patients with and without HCC, 
thereby giving an interpretation of the role played by inflammation in the carcinogenetic 
process. Secondary endpoints are the identification of prognostic markers and future 
therapeutic targets. 
Materials and Methods: Eighty consecutive patients with cirrhosis followed as 
outpatient controls between 2002 and 2012 were included. Twenty-two patients were 
affected by alcoholic cirrhosis, while fifty-eight presented liver cirrhosis and HCC. In 
the group of patients with HCC, forty-four patients underwent loco-regional therapies, 
whereas fourteen underwent surgery. Evaluation of cirrhosis was carried out by Child-
Pugh, MELD and MELD-Na staging systems, ascites, encephalopathy, α-fetoprotein 
levels (αFP), tumour size and overall survival in HCC patients. A group of 20 healthy 
patients was used as control group. 
The evaluation of VAP-1 serum levels was performed by Enzyme Linked 
Immunosorbent Assay (ELISA - Bender MedSystems GmbHc) carried out on plasma 
samples after defrosing. The evaluation of the inflammatory cytokines (IL-6 and TNF-α) 
and of the adhesion soluble forms of cell adhesion proteins (ICAM-1 and VCAM-1) 
were performed by Bio-Plex system (kit Bio-Plex Pro™ kit - Bio-Rad) carried out on 
plasma samples after defrosting. 
Numerical data were expressed as mean and standard deviation and compared with 
Student’s t-test, while for categorical variables count and percentage in each category 
are reported and compared with Wilcoxon test. Cox regression and KaplanMeier 
method were performed for the survival study. Statistical significance was declared for 
P-value <0.05. The statistical analysis was performed with STATA/SE 11.1 
(StataCorpLP, College Station, Texas, USA). 
Results: The analysis of the expression of pro-inflammatory proteins revealed that 
VAP-1 (p=0.001) and VCAM-1 (p=0.005) were significantly higher in cirrhotic patients 
without HCC compared to those with cancer. No statistical difference was assesed in 
levels of TNF, IL-6, ICAM-1, α-FP between the two groups. The group of patients 
treated with medical therapy showed a mean of 5-years survival of 42% and a median 
life expectancy of 38 months, while surgical patients showed a mean 5-years survival of 
55% and a median life expectancy of 97 months. The univariate analysis demonstrated a 
statistical significance with a negative correlation with prognosis for ascites (p=0,012, 
HR 2,7, CI 95% 1,24-5,85) and tumor size (p=0,027, HR 1,01, CI 95% 1,24-5,85). No 
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statistical significance was found at univariate analysis for the other parameters (IL-6, 
TNF-α, VAP-1, ICAM-1, VCAM-1, Child-Pugh, MELD, MELD-Na, Encephalopathy, 
αFP ). At multivariate analysis, tumor size and ascites were shown to be statistically 
significant, with a p respectively of 0.033 (HR 1,01, CI 95% 1,00083-1,02) and 0.02 
(HR 2,54, CI 95% 1,159-5,57). 
Conclusions: In this study VAP-1 and VCAM-1 were significantly higher in cirrhotic 
patients without HCC than in those with cancer. This could suggest a role of these 
molecules in the immune control. Even if in literature ICAM-1 is reported to have a 
higher expression in patients with cancer, in this study the analysis didn’t show any 
differences between the groups. The hypothesis to be investigated is if the upregulation 
of ICAM-1 could lead the loss of immune control against the neoplasm. Moreover, also 
IL-6 and TNF were not statistically significant. Concerning to the prognostic impact, 
only the two clinical parameters ascites and tumor size were statistically significante 
with a negative correlation with prognosis, while none of the molecules have any 
correlation. 
These preliminary results are not conclusive and further studies are needed to clarify the 
intriguing role of cytokines and vascular adhesion protein in carcinogenesis and their 
prognostic value.  
The main limit of this paper is the lack of uniformity of the population studied. The 
different rate of staging subgroups in the various population may have affected the 
statistical analysis. A prospective case-control study is the next postdoc research topic. 
The first endpoint will be the homogenization of the population to be studied, thus 
allowing the evaluation of patients by stage (Child-Pough; Meld) and by etiology of 
cirrhosis (alcoholic, HBV, HCV), and furthermore making a comparison between the 
different categories and subgroups. Furthermore, as secondary endpoint, the study will 
focus on finding potential therapeutic targets and the subsequent therapeutic 
implication. 
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RIASSUNTO 
Introduzione: L’epatocarcinoma (HCC) è la sesta neoplasia e la terza causa di morte 
per cancro a livello mondiale. La sua incidenza in Italia è di circa 10-20 casi/100.000 
all’anno. Il principale fattore di rischio per HCC è la cirrosi epatica e infatti il 70-90% di 
pazienti con HCC ne è affetto. Nel 54% dei casi i pazienti con HCC hanno un’infezione 
da HBV, nel 31% da HCV ed nel 15% un’epatopatia da abuso alcolico. 
L’infiammazione, attraverso l’alterazione del microambiente epatico, gioca un ruolo 
fondamentale nel passaggio da epatopatia a cirrosi e infine a HCC. Fattori chiave 
dell’infiammazione indotta dall’alcool sono le citochine IL-6 e il Tumour Necrosis 
Factor α (TNF), e le proteine d’adesione Vascular Adhesion Protein 1 (VAP-1), 
Intercellular Adhesion Molecule 1 (ICAM-1) e Vascular Cell Adhesion Molecule 
(VCAM-1).  
Scopo dello studio: Lo scopo dello studio è valutare l’espressione di IL-6, TNF, VAP-
1, ICAM-1 e VCAM-1 nei pazienti affetti da cirrosi con e senza neoplasia per verificare 
il ruolo svolto dall’infiammazione nel processo di carcinogenesi. Ulteriore obiettivo è 
l’identificazione di eventuali fattori prognostici e di possibili bersagli terapeutici.  
Materiali e metodi: Sono stati considerati 80 pazienti di cui 22 con cirrosi epatica, 44 
con HCC insorto su cirrosi sottoposti a trattamenti loco-regionali e 14 con HCC insorto 
su cirrosi sottoposti a chirurgia. Tutti i pazienti avevano una cirrosi ad eziologia alcolica 
e sono stati trattati tra il 2002 e il 2012. Per ogni paziente è stato effettuato un prelievo 
di plasma precedente al trattamento o al momento della prima visita ambulatoriale. La 
cirrosi è stata stadiata mediante le classificazioni Child-Pugh, MELD e MELD-Na. Sono 
state inoltre valutati i seguenti parametri: ascite, encefalopatia, α-fetoproteina, 
dimensione del tumore, sopravvivenza. L’analisi dei livelli della forma solubile della 
VAP-1 è stata effettuata tramite test ELISA. IL-6, TNF, ICAM-1 e VCAM-1 sono state 
analizzate tramite il test Bio-Plex Suspension Array. 
L’analisi statistica relativa a VAP-1, IL6, TNF-α, ICAM-1 and VCAM-1, α-FP è stata 
effettuata utilizzando il test parametrico T-test. Gli altri parametri sono stati studiati 
mediante il test non parametrico di Wilcoxon. La sutido di sopravvivenza è statao 
effettuato utilizzando la regressione di Cox e il metodo di Kaplan-Meier method. La 
significatività statistica è stata indicata per P <0.05. Per l’analisi è stato utilizzato il 
software STATA/SE 11.1 (StataCorpLP, College Station, Texas, USA).  
Risultati: Nell’analisi dell’espressione delle proteine proinfiammatorie nei pazienti 
cirrotici con e senza epatocarcinoma sono risultati significativi i valori di VAP-1 e 
VCAM-1. Questi sono risultati significativamente più alti nei pazienti cirrotici con un a 
p=0,001 per VAP-1 e p=0,005 per VCAM-1. Le differenze di valori relative a IL6, 
ICAM-1, TNF e αFP non sono risultati statisticamente significative. Dopo un follow-up 
medio di 5 anni, la sopravvivenza mediana dei pazienti non operati è stata 38 mesi, 
mentre negli operati di 97 mesi. Solo le dimensioni del tumore e la presenza di ascite 
sono risultate significative all’analisi uni variata, dimostrando entrambe un valore 
prognostico negativo (dimensioni del tumore p=0,027, HR 1,01, CI 95% 1,24-5,85;  
ascite p=0,012, HR 2,7, CI 95% 1,24-5,85). Allo stesso modo anche alla multivariata 
sono risultati significativi solo dimensioni del tumore (p=0,033 HR 1,01, CI 95% 
1,00083-1,02) e ascite (P=0,02, HR 2,54, CI 95% 1,159-5,57). 
Conclusioni: L’infiammazione promuove la tumorigenesi creando un microambiente 
infiammatorio e ossidativo che determina un danno cellulare e favorisce l’insorgenza di 
mutazioni genetiche. D’altro canto l’infiammazione contrasta l’insorgenza del tumore 
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tramite il processo dell’immunosorveglianza. IL-6, VAP-1, ICAM-1 e VCAM-1 
giocano un possibile ruolo nel controllo immunitario della neoplasia, per cui nei 
pazienti con tumore dovrebbero presentare valori inferiori. In questo studio però solo 
VAP-1 e VCAM-1 hanno confermato questa ipotesi. TNF, IL6 e ICAM-1 non sono 
risultate significative nonostante il loro importante ruolo nel contesto infiammatorio e 
probabilmente anche nel processo della carcinogenesi, e pertanto il loro ruolo 
nell’epatocarcinoma rimane da chiarire mediante ulteriori studi. Inoltre queste molecole 
non sono risultate significative dal punto di vista prognostico, a differenza dei due 
fattori clinici, ascite e dimensione del tumore. Forse la gravità della patologia epatica 
della popolazione presa in studio ha mascherato il loro effetto. 
Considerato quanto rilevato, i risultati preliminari non paiono conclusivi e pertanto sono 
necessari ulteriori studi per chiarire il ruolo delle citochine e delle proteine di adesione 
vascolare nella carcinogenesi. A riguardo nel prossimo lavoro l’obiettivo principale sarà 
quello di omogeneizzare il più possibile la popolazione in modo tale da poter 
suddividere la stessa per categorie di stadiazione e per eziologia, in modo da effettuare 
dei confronti fra i diversi gruppi con l’obiettivo di interpretare il ruolo di questi fattori 
nell’evoluzione dell’epatocarcinoma nei pazienti cirrotici. 
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BACKGROUND 
 
Hepatocellular carcinoma (HCC) accounts 90% of all primitive liver neoplasms. It is the 
6th commonest neoplasm and the 3rd cause of death for cancer worldwide. HCC is 
predominant among men and its mortality rate is 16/100.000 inhabitants per year in the 
world. Worldwide almost 54% of HCC is attributable to HBV infections, while 30% are 
caused by HCV and 15% by alcohol consumption.1  
Considered that 70-90% of patients are cirrhotic, almost all HCC arise in an 
environment of chronic inflammation and liver injury, suggesting that a proliferative 
and pro-inflammatory tissue state is a common feature of pre-neoplastic livers 
regardless of etiology.2   
 
 
Fig. 1 The pathway from healthy cell to cancer3  
During progression from chronic liver disease to cirrhosis and finally HCC, 
inflammation plays a pivotal role through changes in liver tissue leading to activation of 
several cellular pathways, which promote hepatocarcinogenesis by creating an 
inflammatory and oxidative microenvironment that causes cell damage and genetic 
mutations. Therefore, the inflammatory microenvironment plays a pivotal role in the 
beginning and progression of HCC. 
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The contact between immune cells surface proteins with hepatocytes, and the immune 
cells paracrine signals act on the preneoplastic environment, thus promoting cellular 
proliferation, genetic mutations and chromosomal instability. Once chronic 
inflammation has been established it follows a continuous production of cytokines and 
the recruitment of immune cells. So, if the inflammatory stimulus persists, the process is 
maintained and progresses. TNF and IL-6 are important cytokines in this process. 
Another important evidence is the activation of growth factors and their respective 
signalling pathways, which is a natural response to inflammation and liver damage with 
the aim of tissue repair and regeneration. Several growth factors are involved, among 
them Insulin Growth Factor (IGF), Hepatocyte Growth Factor (HGF), Wnt, Tumour 
Growth Factor Beta (TGF-β) and the signalling pathway of Epithelial Growth Factor 
Receptor (EGFR). In particular, pro-inflammatory cytokines stimulate EGFR ligands 
production, and in hepatitis and liver cirrhosis, as well as in HCC, an increased 
cyclooxygenase 2 (COX2) expression has been demonstrated. High prostaglandin E2 
(PGE2) levels, produced by COX2 were found in malignant cells, thus suggesting a role 
in the initial phases of carcinogenesis. 
 
FACTORS INVOLVED IN HCC CARCINOGENESIS  
Hepatitis viruses2,4  
There is an increase of evidence regarding the ability of HBV and HCV viral proteins to 
cause oncogenic effects directly or to contribute to an increased risk of hepatocellular 
transformation in cooperation with the hyperproliferative response induced by chronic 
inflammation. 
Hepatitis viruses cause chronic liver damage and therefore progression to fibrosis and 
cirrhosis. In any case, HCC may develop even in the absence of cirrhosis. The 
integration of HBV in the host genome causes deletions in DNA, translocations and 
mutations in various chromosomic positions. Several viral factors have been involved, 
including the genes HBx, pre-S2/S and HBV spliced protein. Among these, HBx is 
basic for the hepatocarcinogenesis process. It not only promotes the persistence of viral 
infection starting up the expression of the HBV genome and the replication, but also 
leads to genomic instability through the suppression of p53-regulated DNA repair 
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system. Unlike HBV, HCV is an RNA virus that is not able to perform a reverse 
transcription to DNA. Various HCV proteins such as the envelope and core proteins and 
non-structural proteins have been recognized as carcinogenic. It has also been described 
how these proteins are involved in the regulation of apoptosis and cell proliferation. 
 
Alcohol5-12  
Alcohol was recognized as a cause of chronic liver disease and cirrhosis. It may also 
affect the development of HCC by encouraging the initiation or promotion of the 
neoplasia through various processes: 
- Formation of DNA adducts caused by acetaldehyde, which is produced by 
alcohol dehydrogenase (ADH) and CYP2E1 through the oxidative metabolism of 
alcohol 
- Generation of reactive oxygen species (ROS) generated by the ethanol 
metabolism due to CYP2E1 and NADH oxidation 
 
 
Fig. 2 Mechanisms of Alcohol-Associated Hepatocellular Carcinoma13  
 
- Generation of ROS by the Fenton’s reaction due to iron accumulation within 
Kuppfer cells and hepatocytes 
- Depletion of Glutathione enzymatic activity and liver concentrations 
- Depletion of S-adenosylmethionine (SAM) resulting in DNA hypomethylation 
  
8 
- Depletion of hepatic retinoic acid concentrations and of retinoid signaling  
- Induction of an inflammatory response thus facilitating chronic inflammation of 
and interruption of immunosurveillance  
- Increase of intestinal permeability thus facilitating chronic inflammation  
- Depletion of Natural killer (NK) cells levels and activity 
- Activation of the HedgeHog pathway (HH). 
 
Non-alcoholic steatohepatitis (NASH)  
The main risk factors for the liver disease on metabolic basis are represented by visceral 
obesity, type 2 diabetes mellitus, hypertension and dyslipidemia, i.e. from that set of 
mutually correlated and influenced factors which is called metabolic syndrome. The 
course of the disease goes from steatosis to steatohepatitis up to fibrosis and hepatic 
cirrhosis. Steatohepatitis is characterized by the accumulation of fat vesicles in the 
cytoplasm of hepatocytes, like in steatosis, with in addition the presence of various 
degrees of lobular inflammation, swelling of hepatocytes, apoptosis, necrosis and 
fibrosis. Several mechanisms have been proposed to explain the process of 
carcinogenesis but, in any case, inflammation and generation of ROS play a key role. 
The latter perform the same function already seen in steatohepatitis of alcoholic nature.3 
In addition the visceral fat produces a significant number of molecules, including TNF, 
IL-6, monocyte chemoattractant protein and leptin, secreted by the same adipocytes or 
macrophages there residing, leading to hepatic steatosis and oxidative stress through 
insulin resistance. A recent experimental study on murine models has shown how 
obesity facilitates the development of HCC by stimulating the production of cytokines 
that induce the development of the tumor, such as IL-6 and.14 As for insulin resistance, 
it is a typical characteristic of type-2 diabetes mellitus (DM2), and, indirectly, leads to 
an increased production of insulin in order to maintain adequate blood glucose levels.15 
Insulin resistance and hyperinsulinemia, however, promote the rise of phosphorylation 
and activation of downstream signalling pathways which result in the inhibition of 
apoptosis and increased cell proliferation. Insulin resistance may also hasten 
hepatocarcinogenesis through stimulation of hepatic neovascularization. 
Hyperinsulinemia causes an increased activation of its own receptor, resulting in 
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phosphorylation of IRS-1 factor and activation of both the PTEN/ P12K/ Akt pathway 
and the MAP kinases pathway. PTEN is a tumor suppressor that reduces the stimulus 
towards Akt: its reduction encourages the development of cancer. Akt, on the contrary, 
promotes cell survival by inhibiting BAD protein, of the Bcl-2 proteins group, thus 
counteracting the phenomenon of apoptosis. Insulin causes the up-regulation of hepatic 
growth hormone (GH) receptors, which is the main stimulus for the production of IGF-
1. The latter promotes cell proliferation both through the Akt pathway and through 
activation of MAPK and increased c-fos and c-jun proto-oncogene expression; it 
inhibits apoptosis and facilitates expression of epithelial growth factors. 
Hyperinsulinemia also reduces IGFBP1 and IGFBP2 hepatic synthesis, thus leading to 
an increased bioavailability of IGF-1. Leptin too is involved in the genesis of cancer: it 
is a predominant adipokine in adipose tissue, which acts at hypothalamic level reducing 
appetite and increasing metabolic consumption.  Obesity in humans is often associated 
with high levels of leptin, suggesting that a mechanism of leptin resistance might be 
involved. Leptin secretion is stimulated by cytokines such as IL-1 and TNF, as well as 
by insulin, and increased levels are found both in chronic liver diseases and in HCC. In 
fact it contributes to hepatic fibrogenesis encouraging the expression of TGF-β, which 
in turn activates the stellate cells. As regards cancer leptin activates the JAK/STAT 
signal pathway which in turn facilitates the production of cyclin D1 and cell 
proliferation. Actually, the role played by leptin is far more complex, as evidenced by 
the fact that its expression is often increased in the tissues adjacent to the tumor and 
reduced in the tumor itself, suggesting the hypothesis that it might be involved not in 
cell proliferation but in the angiogenesis process. Finally adiponectin, a hormone 
produced only by adipose tissue, is markedly reduced both in obesity and in resulting 
steatosis, NASH, cirrhosis and HCC.  It has an anti-inflammatory role, but cytokines 
(especially IL-6 and TNF) produced during the continuous chronic inflammatory 
condition of obesity and in the liver disease itself reduce its level. It also has an 
antiproliferative and pro-apoptotic effect through AMPK protein, which is able to stop 
the cell cycle through phosphorylation of other proteins, including for example 
mTOR.15-19 
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From chronic liver disease to cirrhosis and cancer 
All the above mentioned factors lead to liver damage with inflammation and hepatocyte 
necrosis, facilitating the onset of a chronic liver disease. In this context, as a restorative 
response to injury, stellate cells acquire a myofibroblastic phenotype leading to an 
exaggerated deposit of extracellular matrix and then to hepatic fibrosis. This matrix 
deposit often results in reduced blood flow in some parts of the hepatic parenchyma. 
Fibrosis can progress to cirrhosis, during which irreversible architectural changes occur 
with nodule formation, while liver cells lose their normal arrangement. Cirrhosis is 
associated with cancer development but the molecular bases of this process are still 
poorly understood.  However, evidence suggests that there is a sequence of transition 
from dysplasia to carcinoma in a similar way to what happens in other cancer types, 
such as in the colon. Probably the continuous process of necrosis and regeneration with 
an increased cell turnover makes liver cells more sensitive to the adverse effects of the 
various mutagenic agents. Genetic mutations occur of both genetic and epigenetic type, 
leading to the formation of dysplastic foci, nodules and eventually to HCC.3,20,21 
 
Genomic instability 
The alteration of the genetic code is the first cellular event during carcinogenesis and is 
frequently found in many types of cancer. It is acknowledged that the integration of 
HBV DNA is a critical risk factor for genetic damage, but nowadays no specific genetic 
alteration has been found. Non-specific mutations in HCC generally involve β-catenin 
and p53. Furthermore erosion of telomeres, chromosomal segregation defects and 
oxidative DNA damage contribute to genomic instability.2 
 
Oncogenes and signaling pathways 
Hepatocarcinogenesis is a process closely related with the interruption of several 
signaling pathways involved in cellular survival, proliferation, differentiation, and 
apoptosis. These pathways are often intertwined and characterized by aberrant 
expression of protooncogenes or by the loss of tumor suppressor genes. p53 and 
retinoblastoma (RB) are two of the most frequently altered genes in cancer cells. Other 
members of the RB pathway too are often altered, for example D1/CDK4 cyclin, which 
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phosphorylates and inactivates RB, is overexpressed in 58% of HCC. P16, a negative 
regulator of RB, is absent in 34% of HCC. An aberration of Wnt signaling that leads to 
the development of cancer is often caused by an overactivation of β-catenin, whose 
mutation is estimated to be present in 20-40% of HCC. An activation of Akt with PTEN 
overexpression is present in 40% of cancers. Other key molecules are regulated by critic 
signaling pathways that are frequently altered in HCC, such as TGF-β/SMAD, Wnt/β-
catenin, IKK/NF-kB. In addition to these ones, the Hedgehog and Notch signaling 
pathway, which plays a major role during the embryonic development, is often altered in 
HCC.2,22   
 
Fig. 3 Signaling pathway in Hepatocellular Carinoma development2  
 
Oxidative stress and HCC 
Oxidative stress is caused by an excessive production of ROS and of reactive nitrogen 
species (RNS), and at the same time because of the inability to detoxify these products 
and repair the damage. The disposal of ROS and RNS is done mainly through 
glutathione molecules, thioredoxin and enzymatic systems such as superoxide 
dismutase, catalase and glutathione in the transcription of a large variety of cytokines 
and growth factors, which in turn can increase the levels of these reactive species. The 
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main sources of free radicals are represented by mitochondria and by P450 enzymes in 
hepatocytes, as well as by Kupffer cells and neutrophils present in the liver. They have a 
short half-life but they can interact with various classes of molecules such as proteins, 
membrane lipids, DNA and RNA. The caused damage may therefore lead the cell 
towards apoptosis or mutation of the genome. An important cellular defense mechanism 
is represented by various DNA repair systems, which are in turn, though, damaged by 
oxidative stress as well as by HBV infection.3 
 
Cancer stem cells 
Cancer arises from a small and defined subpopulation of cells defined as cancer stem 
cells (CSC). These cells have the self-renewal ability or can differentiate into mature 
cancer cells.23 Scientific evidence supports the fact that CSCs are responsible for the 
hierarchical and heterogeneous organization of HCC. They are characterized by specific 
membrane markers such as EpCAM, CD13, CD24, OV-6, CD44 and ALDH. Many 
chemotherapy drugs are directed against mature cancer cells, having little or no 
effectiveness against CSCs; therefore it would be crucial to find some medicines 
suitable for this subpopulation. When CSCs migrate into the blood vessels they become 
circulating CSCs, playing a fundamental role in metastasization and formation of tumor-
based portal thrombosis. A problem concerns the origin of these cells: adult hepatocytes 
still possess staminal properties since they are capable of proliferation in response to a 
liver injury, being able to differentiate both towards hepatocytic lineage and, under 
particular circumstances, towards biliary lineage. It is possible that hepatocytes de-
differentiating may become CSCs and trigger the tumor. Another possible origin is from 
the hepatic progenitor cells, undifferentiated cells that normally reside quiescent in the 
bile ductules and in the canals of Hering, being able to differentiate towards both 
hepatocytic and cholangiocytic lineage. These cells when exposed to preneoplastic 
conditions, such as chronic inflammation, can turn into CSCs. Continuous exposure of 
TGF-β in vitro transforms these cells into CSCs. It is widely accepted that the 
development of HCC is caused by the propagation of these CSCs, although the 
molecular mechanism still remains unclear. Several studies have shown that there is a 
network of signals involving TGF-β, JAK/STAT3, Notch and PI3-K/Akt/mTOR.2,24 
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Hepatic progenitor cells are small cells with a large nucleus and a thin rime of 
cytoplasm around; in animals they are also called oval cells. Recently it has been shown 
that in a cirrhotic liver cells become senescent due to a shortening of telomeres. Some 
senescent cells acquire additional mutations and a subsequent gain in replicative 
capacity, making it likely that at least a part of HCC arise from a hepatic progenitor cell. 
 
Tumor microenvironment 
Several studies have shown how the tumor microenvironment plays a pivotal role in 
tumorigenesis and neoplastic progression. Cancerous cells are not as autonomous as it 
was thought once: they are dependent on angiogenesis, inflammatory cells and 
fibroblasts. Obviously in the cirrhotic liver there are plenty of fibroblasts, and there is 
evidence that some of them are cancer-associated fibroblasts (CAF). In HCC the 
progression of malignant hepatocytes often depends on the TGF-β provided by stromal 
cells (macrophages, fibroblasts etc.). This molecule is one of the factors that may induce 
a mesenchymal-epithelial transition (EMT). For different types of cancer it has been 
noticed that an EMT is associated with a worse prognosis, such as for example in 
esophageal squamous cell carcinoma, in stomach, bladder cancer, in non-small cell lung 
cancer as well as in pancreatic ductal adenocarcinoma. The characteristics of EMT are a 
change in gene expression with overexpression of twist, snail, VE-cadherin, vimentin 
and a down-regulation of E-cadherin, HNF4α hepatocyte transcription factor and 
changes in the cytoskeleton. In EMT there is a destabilization of anchoring junctions 
and the cell develops enhanced invasive properties. In animal models, it has been 
noticed how EMT promotes neoplastic invasion and metastasization. Both HBV and 
HCV, in addition to a hypoxic condition, promote EMT.3,25-29 
 
Hypoxia and tumor progression 
Hypoxia is involved in the angiogenesis process through the HIF-α 1 pathway which 
stimulates the expression of pro-angiogenic factors, as well as induces EMT. 
Furthermore, chronic exposure to an hypoxic environment is likely to lead to an 
adaptation of the genetic expression profile of cancer cells, giving them a more 
aggressive behavior.3 
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INFLAMMATION AND CARCINOGENESIS 
Epidemiological studies have established a relationship between chronic inflammatory 
diseases and cancers, and it is well known that a persistent inflammatory condition 
increases the risk of cancer and facilitates carcinogenesis. The presence of an 
inflammatory microenvironment plays an essential role in HCC initiation and 
progression. The infiltration of inflammatory cells can be caused by necrotic or 
apoptotic hepatocytes. Various cytokines and chemokines, secreted by immune cells and 
the direct contact between the surface proteins of immune cells and hepatocytes, 
remodel the preneoplastic microenvironment, promoting genetic mutations and cell 
proliferation. TNF and IL-6 are the main cytokines in this process.2 
 
 
Fig. 4  Vie molecolari che collegano l’infiammazione allo sviluppo di HCC30 
 
Another common finding in chronic inflammatory liver diseases and in HCC is the 
activation of growth factors and their respective signaling pathways. This is a natural 
response to inflammation and damage of liver tissue with the aim of a tissue 
regeneration and repair. In any case, when chronically stimulated or dysregulated by 
molecular or functional changes, these growth factors may contribute to the neoplastic 
transformation and to the maintenance of the transformed phenotype of HCC cells. 
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There are different growth factors involved, including insulin-like growth factor (IGF), 
HGF, Wnt, TGF-β and the EGFR signaling system. In particular in murine models it has 
been noticed that HGF is involved in carcinogenesis through autocrine activation of the 
HGF-Met pathway. Furthermore, overexpression of EGFR has been described in HCC 
samples, and a correlation has been identified between high levels of EGFR and adverse 
prognosis. Similarly also EGFR ligands (TGF-α, HB-EGF, BTC and AR) have been 
found in a high percentage of HCC. On the contrary the specific deletion of EGFR in the 
liver parenchyma of murine models results in a weakening of hepatic proliferation in the 
early stage of regeneration, and the specific deletion of its ligands leads to a reduction of 
cell proliferation. The administration of gefitinib, an inhibitor of EGFR molecule, 
prevented chemically induced HCC in mice. All this evidence support the involvement 
of a dysregulation of EGFR in the multistep process leading to carcinogenesis. 
Important informations have also been obtained on its interaction with the classic 
signaling pathways involved in inflammation.  These interactions can be observed at 
different levels from the mechanisms that regulate expression and availability of EGFR 
ligands, including their cellular origin, to their effect on target cells. Expression of 
EGFR ligands is generally increased in acute and chronic inflammation. Within the liver 
parenchyma these factors can be produced not only by hepatocytes and by cells that 
produce extracellular matrix, but also by inflammatory cells such as Kuppfer cells and 
resident macrophages. This has been demonstrated for AR, HB-EGF and TGF-α.30-35  
Moreover the platelet derived growth factor (PDGF), produced by the activated Kuppfer 
cells, can facilitate the production of AR in cells that produce extracellular matrix. Even 
expression of HB-EGF can be induced in non-parenchymal liver cells through 
stimulation of LPS. Furthermore liver cells may express different EGFR ligands when 
stimulated with pro-inflammatory cytokines such as for example TGFα under stimulus 
of TNF and AR for IL-1 β. In addition TGF-β, another growth factor produced by non-
parenchymal liver cells during inflammation, can facilitate the expression of HB-EGF 
and TGF-α. Proinflammatory cytokines, besides stimulating the expression of these 
ligands, can also induce their release on cell surface thanks to the mediation of ADAM 
family metalloproteinases. Thus, it is not surprising that the expression of ADAM17 is 
overexpressed in chronic liver diseases and HCC.   
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The EGFR signaling system has relationship with many other pathways involved in 
inflammation, as that one mediated by COX2 which results in prostaglandin production. 
The importance of this pathway has already been demonstrated in colon cancer, but it is 
also involved in hepatocarcinogenesis. Increased expression of COX2 has been found in 
hepatitis and liver cirrhosis, as well as in both experimental and human HCC. High 
levels of PGE2, produced by COX2, can be found in malignant cells and they are 
thought to contribute to the initial stages of carcinogenesis, including cancer cell 
proliferation, cell survival, invasiveness, angiogenesis, and metastasizing ability. Data 
are now available also about how, in both experimental and human HCC cell lines, 
COX2 inhibitors have the ability to inhibit the cell growth. The mechanisms have not 
yet been understood clearly, even if there seems to exist a strong correlation between 
EGFR signaling pathways and COX2. Probably the activation of EGFR up-regulates the 
expression of COX2, which in turn, through the production of PGE2, activates EGFR. 
PGE2 is also able to facilitate the expression of EGFR ligands such as AR. COX2-
derived prostanoids could be a key signal in the activation of EGFR from the early stage 
of liver inflammation to cancer.30,36-38 
 
IL-6 
IL-6 is a pleiotropic cytokine, expressed in many inflammatory cells in response to 
different types of stimuli and cellular processes, including cell proliferation and 
differentiation, and plays a central role in the acute phase response and in the control of 
balance between proinflammatory and anti-inflammatory pathways. High levels of IL-6 
have been found in several inflammatory and neoplastic conditions, and particularly in 
liver diseases as chronic viral hepatitis, alcohol-related liver disease, liver cirrhosis and 
HCC.39,40 
Chronic inflammation plays a central role in cancer initiation and promotion. The effect 
of the immune system in the inflammatory process that leads to carcinogenesis is the 
stimulation of tumor growth. In the case of chronic inflammation, the balance between 
Th1 and Th2 cytokines in the adaptive immune response is often altered in cancer 
patients, and increased levels of Th2 cytokines can enable an immune escape of cancer 
cells. In fact, high levels of Th2 cytokines such as IL-4, IL-6 and IL-10 are associated 
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with adverse prognosis. Furthermore, IL-6 is a negative independent prognostic variable 
factor in patients with HCC.  IL-6 levels also have a positive correlation with tumor size 
and stage of HCC, as well as with tumor aggressiveness. IL-6 is indeed considered as a 
Th2 cytokine, although actually it takes part in both Th1 and Th2 processes. This all 
supports the hypothesis that in the tumor a shift from Th1 to Th2 immune responses 
may suppresses the host antitumoral immune response, promoting the neoplastic 
growth. 
Several studies have suggested various biological mechanisms for the 
hepatocarcinogenic action of IL-6. Liver cirrhosis is associated with increased levels of 
mRNA expression of IL-6, with increased values according to Child-Pugh class, and IL-
6 gene expression is up-regulated by the hepatitis B virus x protein (HBx), leading to 
oncogenic transformation.41-43 Obesity and diabetes mellitus are recognized risk factors 
for HCC: it has been shown that visceral fat leads to an increased expression of 
cytokines, such as for example TNF and IL-6.14 It was also demonstrated how the HCC 
cells can produce IL-6, by stimulating the tumor growth through an autocrine 
mechanism.43 IL-6, produced by inflammatory and stromal cells within the tumor 
microenvironment, binds to the gp80 (IL-6 receptor)/gp130 complex, leading to the 
activation of a constitutive Janus kinase (Jak) and then to STAT3 phosphorylation, 
which finally can activate the expression of oncogenes that mediate the proliferation and 
inhibit apoptosis.14,44 Finally it has been noticed how some polymorphisms of this 
cytokine are associated with an increased risk of both chronic liver disease and HCC, in 
particular 174 G/C polymorphism, which involves the IL-6 gene regulatory region, 
leading to an overexpression of the cytokine itself. It has been noticed that in this group 
the risk of HCC is increased compared with the one with the normal variant of the IL-6 
gene.40  
 
Tumour necrosis factor α (TNF) 
Among the factors secreted by inflammatory cells associated with tumors, TNF has been 
identified as one of the main molecule that regulate inflammation and it is considered a 
potential mediator in cancers related to inflammation.45 Therefore TNF is a powerful 
cytokine that regulates cell proliferation, survival, migration and angiogenesis.46,47 
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To promote all these changes it acts through various pathways. First, through TNFR1 
factor it activates the NF-kB key inflammatory transcription factor. It plays a very 
complex role in cancer development, in fact its inactivation leads to a greater number of 
tumors in mice treated with the carcinogen DEN. Conversely, inhibition of NF-kB in 
parenchymal cells in the later stages of cancer results in a reduction of tumor 
progression. These apparently conflicting data actually must be evaluated depending on 
the time period of inhibition of NF-kB and the various cellular targets that are involved. 
It has been shown how the loss of NF-kB in hepatocytes elicits carcinogenesis induced 
by chemical compounds through the activation of c-jun N-terminal kinase 1 (JNK1). In 
addition, the deletion of JNK1 causes a reduced hepatocellular damage and a block in 
the development of HCC, confirming in vivo the cytotoxic consequences of a prolonged 
activation of JNK1.  These observations, when considered all together, show the 
essential role of NF-kB and of its dialogue with JNK1 in protecting hepatocytes. 
Therefore the preservation of hepatocyte survival may indirectly reduce tumorigenesis 
by attenuating the compensatory proliferative response during cirrhosis, which allows 
hepatocytes, even with mutations, to enter the cell cycle.48,49 
TNF also activates other molecules. One of these is Forkhead box M1 (FoxM1), a 
ubiquitous transcription factor that, by affecting different target genes, acts as a key 
regulator of the cell cycle both in the transition from G1 to S phase, and in the 
progression to the mitosis phase. Several studies have reported that FoxM1 is 
overexpressed in HCC cells and is an indicator of adverse prognosis. In addition to 
TNF, it is overexpressed through the RAS pathway and also under hypoxic conditions, 
in fact hypoxia-inducible factor (HIF-1) is a critical mediator in the induction of FoxM1 
by TNF. The coexpression of FoxM1 and HIF-1 in HCC cells is an indicator of adverse 
prognosis. Finally another way in which TNF can facilitate the process of carcinogenesis 
is represented by its own pro-inflammatory action, which increases the generation of 
ROS and subsequent cellular damage. The same production of ROS, moreover, is able 
to stabilize the HIF-1 factor, and then facilitate the proliferative pathway mediated by 
HIF-1 and FoxM1.45,50,51 Furthermore, TNF stimulates the production of TNF-induced 
protein 8-like 2 (TNFAIP8L2), which acts as negative regulator of innate and adaptive 
immunity. It also facilitates cell apoptosis, induced by caspase 8 and Fas. It has been 
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noticed that this protein is able to inhibit the metastasization process of HCC, whereas 
its lack facilitates the spread of the tumor. Its action is mainly due to the ability to 
suppress the polymerization of F-actin and the expression both of metalloproteinase-9 
and of the urokinase-type plasminogen activator (uPA), which are essential for the 
migration and cell proliferation leading to the metastatic process.52 Finally, as for IL-6, 
the presence of polymorphisms that add an increased risk of HCC has been detected. In 
particular the 308 G > A variant has been evaluated in several studies, and a meta-
analysis carried out on 20 studies with 2763 patients with HCC and 4152 controls has 
shown an OR of 1.84 for this polymorphism.53  
 
Vascular Adhesion Protein 1 (VAP-1) 
VAP-1 is a human endothelial sialoglycoprotein whose cell expression is induced in 
case of inflammatory conditions. It participates in the lymphocyte recirculation 
mediating their link with endothelial cells.54 VAP-1 forms a homodimer of 180 kDa, 
expressed on vascular endothelium. In vitro it has been noticed how essential it is for 
the mechanism of leukocyte rolling, for the firm adhesion and the migration during the 
extravasation process.55 In addition to these adhesion abilities it also has enzymatic 
properties. Indeed it is also referred as semicarbazide-sensitive amine oxidase (SSAO), 
or aminoxidase containing copper (AOC3), which catalyzes the oxidative deamination 
of primary amines. This is not a matter of secondary importance, since its catalytic 
ability is as fundamental as the adhesive ability.56 It is expressed early in utero and is 
functionally active long before birth. It is likely to contribute to oxidasic activities, 
besides being of crucial importance in lymphocyte traffic during the ontogenetic 
process.55,57 VAP-1 is a fundamental protein involved in several inflammatory 
processes, in fact it promotes lymphocyte homing on endothelial cells at the level of the 
peripheral lymph nodes and of inflammation sites. It is constitutively expressed on 
endothelial cells of the human liver but not very present in the blood vessels of non-
lymphoid organs in non-inflammatory conditions.58  In these cases it is stored in 
intracellular granules and then brought to the surface if needed.59 It is up-regulated in 
the high endothelial venules of the peripheral lymph nodes in case of inflammation. Its 
expression is increased in experimental models of arthritis, in the inflamed lung 
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compared to the normal lung and in endotoxin-induced uveitis.58,60  It was also pointed 
to as a factor involved in the rejection of liver transplant.61  The enzymatic activity of 
VAP-1 is also responsible for the formation of free radicals such as hydrogen peroxide 
and ammonium that lead to a cytotoxic damage of the endothelial cells. In addition, 
hydrogen peroxide is an important signaling molecule that leads to an increased 
expression of CD62P and VCAM-1 adhesive proteins (vide infra), as well as to 
chemokine and metalloproteinase receptors. In this way the ongoing inflammatory 
process is enhanced. VAP-1 is also involved in inflammatory processes relating to 
cardiovascular diseases, diabetes, obesity and hypertension. All this makes this molecule 
a possible target for inhibitor drugs.60  
Another important correlation exists between VAP-1 and diabetes: as previously stated 
VAP-1 levels are increased in diabetic subjects and it accounts for the pathogenesis of 
some of its complications such as for example retinopathy. In the retinal vessels VAP-1, 
along with other adhesion proteins such as ICAM-1 and VCAM-1, facilitates the 
leukocyte adhesion, thereby contributing to the genesis of diabetic retinopathy.62  
Altered expression of VAP-1 is present in several types of cancer: in stomach cancer 
low levels of sVAP-1 (soluble form of VAP-1) are associated with adverse prognosis.63 
In the same way lower levels are present in colon cancer and these are associated with 
adverse prognosis besides being predictive of lymphatic and hepatic metastases.64 These 
results are explained by the fact that the tumor infiltrating lymphocytes (TILs) act 
against the growth of the tumor.63,64  On the contrary in melanoma the intratumoral 
vessels have been shown to possess low levels of VAP-1 while the peritumoral vessels 
overexpress VAP-1. This difference is probably due to the transport of different types of 
molecules, some of which are probably involved in angiogenesis with respect to the 
peritumoral vessels.65  
In the liver the hepatic endothelial cells form a specialised endothelium that supports 
lymphocyte adhesion and recruitment in a low flow optimal environment. The hepatic 
endothelium has a different phenotype than other vascular beds. In vivo the hepatic 
endothelium expresses low levels of CD31, which is among the most represented 
adhesion factors in other tissues. VAP-1 in the hepatic endothelium promotes 
lymphocyte adhesion in laminar shear stress conditions. It is a mediator of the 
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transendothelial lymphocyte migration but its ability to facilitate cell adhesion and 
migration is blocked by specific inhibitors of its enzymatic activity. In some studies 
increased levels of VAP-1 in patients with HCC have been identified. These findings 
suggest that increased levels of VAP-1 contribute to high lymphocyte adhesion on the 
vascular endothelium at the periphery of primitive liver tumors.  
This mechanism might increase the immune response to the tumor, while other adhesion 
molecules involved in the multistep process of adhesion are also high in primary liver 
tumors. The increased expression of VAP-1 is specific to hepatic tumors because other 
non-hepatic tumors are not associated with elevated levels of VAP-1. Therefore it may 
be a molecule that is expressed in hepatic tumor vessels but is down-regulated in some 
tumors during the growth of the malignant process or not up-regulated in other 
cases.66,67 The underlying liver disease too affects the expression of VAP-1, in particular 
it has been noticed that patients with HCC associated with a liver disease with alcoholic 
etiology have higher levels of VAP-1 compared to other patients with HCC. It is 
generally higher among patients with HCC, while it is not high either among patients 
with HCC associated HCV or in those who have HCC associated with steatohepatitis, 
while patients with a diagnosis of cirrhosis from steatohepatitis without HCC have high 
concentrations. The mechanism is still unclear.68  
Intercellular Adhesion Molecule 1 (ICAM-1) 
ICAM-1 is a highly glycosylated single-chain glycoprotein with a polypeptide core of 55 
kD belonging to the immunoglobulin superfamily.69,70  The main function of ICAM-1 is 
to participate in the recognition and adhesion between cells. Its molecular counterpart in 
this bond is recognized in two proteins: lymphocyte function-associated antigen (LFA-
1) and the macrophage surface antigen (Mac-1). ICAM-1 is an essential molecule for the 
interaction between T lymphocytes and fibroblasts, as well as for the agglutination 
between lymphocytes and lymphocytes or between lymphocytes and endothelial cells. 
The expression of ICAM-1 is relatively increased in metastatic tumors. Furthermore 
along with the cancer cells that express different levels of ICAM-1, lymphocytes with 
ICAM-1 can be found in almost all cancers. Various cytokines can facilitate its 
expression through the activation of NF-kB signaling pathway. 
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In the healthy liver hepatocytes do not express ICAM-1 while endothelial cells of liver 
sinusoids and endothelial vascular cells have a weak expression of ICAM-1. In various 
types of hepatitis the expression of ICAM-1 is increased in endothelial cells of liver 
sinusoids and in endothelial vascular cells and it is positive also in hepatocytes, 
cholangiocytes, lymphocytes and fibroblasts. Serum ICAM-1 levels are significantly 
higher in patients with liver cirrhosis: here it plays a major role, especially in cases 
where cirrhosis is associated with HCC. In fact most of the cell types present in 
primitive hepatic tumors are cancer-associated fibroblasts (CAF). They play an 
important role in neoplastic invasion, angiogenesis and metastasization process. The 
normal fibroblasts can promote cells’ differentiation and inhibit the growth of cancer 
cells but CAFs, in contrast, can stimulate the tumoral growth and infiltration. The tumor 
microenvironment full of IL-6 and ICAM-1 expressed by CAFs facilitates metastases. 
The CAFs activated by pro-inflammatory cytokines such as TNF are an important 
source of ICAM-1.69  
The levels of ICAM-1 in patients with HCC are reported to be significantly higher than 
normal. The expression of ICAM-1 is different between the areas of normal liver, of 
atypical hyperplasia and of HCC.71 The expression of ICAM-1 in endothelial and 
mesenchymal cells is inversely proportional to the degree of atypical hyperplasia, but on 
the contrary its expression in hepatocytes is significantly higher than in non-neoplastic 
liver cells. In fact, ICAM-1, besides being secreted by immune cells stimulated by tumor 
antigens, is also released by the cancer cells themselves, which could be one of the 
molecular mechanisms of tumor immune escape. The level of ICAM-1, moreover, 
increases with the stage of the tumor, while it declines after surgical resection.69  
It has also been discovered how ICAM-1 positive cancer cells are able to induce tumors 
in vivo, showing that HCC cells expressing ICAM-1 possess properties typical of cancer 
stem cells. Then the conclusion was reached that ICAM-1 could be used as a potential 
marker for CSCs. In fact the specific inhibition of ICAM-1 expression in vivo reduces 
the development of HCC and metastases, suggesting that this molecule could be used as 
a therapeutic target. The fact that CSCs isolated from the same tumor may express 
different markers suggested that there are different populations of CSCs, among which 
the main one would be positive ICAM-1. Moreover, the presence of positive ICAM-1 
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cancer cells in the blood of patients with HCC provides evidence of the existence of 
circulating tumor cells (CTC), which are also thought to possess CSC properties, and to 
be in turn a heterogeneous set of cell populations.72  
The expression of ICAM-1 is strongly correlated to the size of the tumour and to the 
development of metastases. Probably ICAM-1, combining with its natural ligand LFA-
1, allows the cancer cells to reach the blood stream along with lymphocytes. Other 
studies suggest that ICAM-1 may play a role in the disintegration of the cell adhesion 
local system, in cellular contractions and in the cytoskeletal reconstruction, so as to 
facilitate the migration of the cells themselves. Moreover, a high expression of ICAM-1 
helps the cells separate from each other and move. Finally, it is important for 
angiogenesis too, in fact along with VCAM-1 it promotes the expression of various 
cytokines, which in turn encourage the formation of vessel intima. Even isolated tumor 
endothelial cells (TECs) and normal endothelial cells express ICAM-1 on the surface 
and are responsible for the formation of capillaries. 
The diagnostic and prognostic role of ICAM-1 was also studied. It has been noticed in 
fact that, in patients with negative AFP, space-occupying lesions have been found 1 to 4 
months after the discovery of abnormally high levels of soluble ICAM-1 (> 1000 
microg/l). ICAM-1 levels are higher in patients with HCC versus those with benign 
tumors and normal controls, and its expression increases with the stage of cirrhosis. It is 
also important in the evaluation of the conditions of HCC patients and of the effects of 
treatments.69,70,73  
 
Vascular Cell Adhesion molecule 1 (VCAM-1) 
VCAM-1 is a transmembrane glycoprotein that belongs to the immunoglobulin 
superfamily. It is one of the adhesion molecules involved as mediators in angiogenesis. 
VCAM-1 is expressed transiently in vascular endothelial cells activated in response to 
VEGF and other cytokines such as TNF, IL-1β and IFN-gamma. Functionally, its 
expression plays a crucial role in the adhesion of leukocytes to the endothelium in 
tissues involved in inflammatory processes and in neoplastic diseases. It also plays an 
important role in providing an attachment to the endothelium during angiogenesis, as 
well as acting as an adhesion molecule to facilitate the development of metastases, for 
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example in melanoma. It is present in soluble form too and as such it can be found in 
circulation. 
VCAM-1 is overexpressed in various neoplastic and non-neoplastic diseases. Some 
studies have shown high serum levels of VCAM-1 in patients with colorectal cancer, 
stomach and breast cancer, as well as being an indicator of adverse prognosis in patients 
with Hodgkin lymphoma. 
Increased expression of VCAM-1 has been reported in chronic liver diseases, suggesting 
that VCAM-1 may play a certain role in the pathogenesis of chronic liver diseases and 
cirrhosis of the liver. Higher serum levels of VCAM-1 were found in several studies on 
chronic liver diseases regardless the etiology. The average level of VCAM-1 in patients 
with HCC is similar to that of healthy controls, however in patients with HCC and 
cirrhosis the level is higher. Furthermore high serum levels of VCAM-1 have a positive 
correlation with serum bilirubin levels, and inversely with albumin values and platelet 
count. This indicates how the levels of VCAM-1 in serum are linked to the severity of 
the underlying liver disease while, on the contrary, there is no statistically significant 
correlation between expression of VCAM-1 and tumor size, its pathologic 
characteristics, stadium or invasiveness. This is in contrast to many other types of cancer 
where high levels of VCAM-1 are associated with a more advanced stage of malignant 
disease. Probably in the liver VCAM-1 plays a less important role as a mediator in 
angiogenesis or other pathological processes in HCC. In fact Yoong et al. have shown 
how in HCC there are higher levels of VAP-1 and ICAM-1 rather than VCAM-1. The 
serum level of VCAM-1 in patients with HCC on non-cirrhotic liver is lower compared 
to normal controls, making it possible to assume that VCAM-1 is down-regulated in 
patients with HCC. On the contrary, instead, VCAM-1 appears to be important in liver 
inflammation and in the development of fibrosis, probably by mediating interactions 
between lymphocytes and endothelium. Finally it has been noticed how lower values of 
VCAM-1 are associated with a longer disease-free time compared to those with higher 
values. This is owing, more than to HCC characteristics, to the fact that higher levels are 
due to a worse liver disease, which in turn correlates positively with a greater risk of 
relapse.74-81 In contrast to this study, other researchers have proposed instead a role of 
VCAM-1 in the development of HCC. For example, Hong Li et al. have noticed how 
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VCAM-1 is an important mediator in the signaling pathway going from the activation of 
HIF-1 α to the expression of angiopoietin-like protein 4 (ANGPTL4), which promotes, 
among its varied and complex tasks, angiogenesis in HCC. Finally, Song et al. and 
Alexander et al. too have shown the role of VCAM-1, together with ICAM-1, in 
angiogenesis in ongoing HCC.82  
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AIMS 
The main aim of the study is to evaluate IL-6, TNF, VAP-1, ICAM-1 and VCAM-1 
expression in serum samples of cirrhotic patients with and without HCC, thereby giving 
an interpretation of the role played by inflammation in the carcinogenetic process. 
Secondary endpoints are the identification of prognostic markers and future therapeutic 
targets. 
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MATERIALS AND METHODS 
Eighty consecutive patients with cirrhosis followed as outpatient controls between 2002 
and 2012 at Azienda Ospedaliera di Padova were included. Twenty-two patients were 
affected by alcoholic cirrhosis, while fifty-eight presented liver cirrhosis and HCC. In 
the group of patients with HCC, forty-four patients underwent loco-regional therapies, 
whereas fourteen underwent surgery. 
Evaluation of cirrhosis was carried out by Child-Pugh, MELD and MELD-Na staging 
systems (tab. 2 to 4), ascites, encephalopathy, α-fetoprotein levels (αFP), tumour size 
and overall survival in HCC patients. A group of 20 healthy patients was used as control 
group. All patients were checked for the presence of diabetes. 
The evaluation of soluble VAP-1 serum levels (sVAP-1) was performed by Enzyme 
Linked Immunosorbent Assay (ELISA - Bender MedSystems GmbHc) carried out on 
plasma samples after defrosting. The evaluation of the inflammatory cytokines (IL6 and 
TNF-α) and of the adhesion soluble forms of cell adhesion proteins (ICAM-1 and 
VCAM-1) was performed by Bio-Plex system (kit Bio-Plex Pro™ kit - Bio-Rad) carried 
out on plasma samples after defrosting. 
Numerical data were expressed as mean and standard deviation and compared with 
Student’s t-test, while for categorical variables count and percentage in each category 
are reported and compared with Wilcoxon test. Cox regression and KaplanMeier 
method were performed for the survival study. Statistical significance was declared for 
P-value <0.05. 
The statistical analysis was performed with STATA/SE 11.1 (StataCorpLP, College 
Station, Texas, USA). 
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RESULTS 
This study included 80 patients followed through outpatient controls between 2002 and 
2012. The mean follow-up was 5 years. Patients were divided into 3 groups: 22 cirrhotic 
patients without HCC, 44 cirrhotic patients with HCC who underwent loco-regional 
therapies, and 14 cirrhotic patients with HCC who underwent surgical procedures. 
 
 
 
In the first group 13 were male and 9 females. The mean age was 54 years (range 43-
77). 3 patients were Child A (13,6%), 11 Child B (50%) and 8 Child C (36,4%). 7 
Tab. 1 staging of cirrhosis in the three groups  
Group Patients Therapy Sex Age Child A Child B Child C 
Cirrhotic 
patients 
22 Medical 
Therapy 
13 male 
9 female 
54 (43-77) 3 11 8 
     MELD 
≤13 
MELD  
13-19 
MELD 
≥19 
     7 9 6 
     MELD-
Na ≤13 
MELD-Na 
13-19  
MELD-Na 
≥19 
     5 9 8 
 
        
     Child A Child B Child C 
Cirrhotic 
patients  
+ HCC 
44 Loco-
regional 
therapies 
34 male 
10 
female 
62 (35-89) 22 15 7 
     MELD 
≤13 
MELD  
13-19 
MELD≥19 
     29 11 4 
     MELD-
Na ≤13 
MELD-Na 
13-19  
MELD-Na 
≥19 
     25 10 13 
 
        
     Child A Child B Child C 
Cirrhotic 
patients 
+ HCC 
14 Surgical 
procedures 
13 male 
1 female 
63 (38-83) 12 2 0 
     MELD 
≤13 
MELD  
13-19 
MELD≥19 
     14 0 0 
     MELD-
Na ≤13 
MELD-Na 
13-19  
MELD-Na 
≥19 
     14 0 0 
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patients were MELD ≤13 (31,8%), 9 between 13 and 19 (41%), 6 patients >19 (27,2%). 
5 patients has a MELD-Na ≤13 (22,7%), 9 between 13 and 19 (41%), 8 patients >19 
(36,3%).  
In the second group 34 were males (77,3%) and 10 females (22,7%). The mean age was 
62 years (range 35-89). 22 patients were Child A (50%), 15 Child B (34,1%) and 7 
Child C (15,9%). 29 were MELD ≤13 (66%), 11 between 13 and 19 (25%), 4 patients 
>19 (9%). 25 patients has a MELD-Na ≤13 (56,8%), 10 between 13 and 19 (22,7%), 13 
patients >19 (20,5%).  
In the third group 13 were males and 1 female. The mean age was 63 years (range 38-
83). 12 patients were Child A (85,7%) and 2 Child B (14,3%). All patients have a 
MELD and MELD-Na ≤13 [Tab. 1].  
Glycemia was checked to exclude diabetes when blood sugar level was less than 5,6 
mmol/l. 
All patients were studied with abdominal ultrasound, abdominal CT scan wit contrast or 
MRI with hepatospecific contrast, thorax CT scan with contrast, bone scintigraphy. All 
patients who underwent surgery were also studied with an intraoperatory liver 
ultrasound. Surgery was radical (R0) in all patients.  
First, a comparison between cirrhotic patients without HCC and healthy controls was 
carried out. A statistical significant difference was found comparing the mean value of 
each pro-inflammatory molecule between the two groups (p<0.05). 
Once proved the difference between cirrhotic patients and healthy controls, the 
evaluation of the parameters was carried out comparing cirrhotic patients without HCC 
to those with HCC.  
VAP-1 (p=0.0005) and VCAM-1 (p=0.001) were significantly higher in cirrhotic 
patients without HCC compared to cirrhotic patients with HCC [fig. 5-6]. No statistical 
difference was assesed in levels of the other parameters αFP, TNF-α, IL6 and ICAM. 
[Tab. 2] 
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Fig. 5  Difference in VAP-1 expression between cirrhotics patients with and without HCC 
 
 
Fig. 6  Difference in VCAM-1 expression between cirrhotics patients with and without HCC 
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Tab. 2: comparison of values in cirrhotic patients with and without HCC 
Parameter Mean value in cirrhotic 
patients 
Mean value in cirrhotic 
patients with HCC 
 
P value 
IL6 13.85 12.12 0.702 
TNF α 5.37 6.93 0.348 
VAP-1 1033,30 683,60 0.001 
ICAM-1 369942 373875 0.960 
VCAM-1 797566 572553 0.005 
αFP 2,61 3601,00 0.455 
 
 
The survival analysis has demonstrated a mean 5-years survival of 47% and a median  
life expectancy of 40 months (fig. 7).  
 
 
Fig. 7  Kaplan-Meier curve of patients with HCC who underwent surgery or locoregional therapy 
 
The group of patients treated with medical therapy showed a mean of 5-years survival of 
42% and a median life expectancy of 38 months (fig. 8), while surgical patients showed 
a mean 5-years survival of 55% and a median life expectancy of 97 months (fig. 9). 
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Fig. 8  Kaplan-Meier curve of patients with HCC who underwent locoregional therapy 
 
 
Fig. 9  Kaplan-Meier curve of patients with HCC who underwent surgery 
 
 
The univariate analysis has demonstrated a negative correlation between prognosis and 
the following parameters: ascites and tumor size. The death risk among those patients 
with ascites was 2.7 times higher compared with those without, suggesting ascites as a 
marker of poor prognosis (p=0.012). Also tumour size was shown as a marker of poor 
prognosis  (p=0.027), with an HR of 1.01. No statistical significance was found at 
univariate analysis for the other parameters (IL-6, TNF-α, VAP-1, ICAM-1, VCAM-1, 
Child-Pugh, MELD, MELD-Na, Encephalopathy, αFP ). [tab. 3] 
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Tab. 3 Overall Survival at univariate analysis 
Parameter Hazard Ratio CI 95% P 
value 
IL6 0.98 0.958 - 1.01 0.404 
TNF-α 0.95 0.873 - 1.03 0.242 
VAP-1 0.999 0.998 - 1 0.317 
ICAM-1 1.000001 0.999 - 1 0.342 
VCAM-1 1 0.999 - 1 0.83 
Child-Pough 2.51 0.445 - 5.716 0.086 
MELD 1.03 0.966 - 1.104 0.341 
MELD-Na 1.04 0.983 - 1.103 0.166 
Encephalopathy 2.24 0.840 - 6.003 0.107 
Ascites 2.702 1.246 - 5.858 0.012 
Tumor Size 1.01 1.001 - 1.019 0.027 
αFP 1 0.9999 - 1 0.306 
 
At multivariate analysis, tumor size and ascites were shown to be statistically 
significant, with a p respectively of 0.033 (HR 1.01 CI 95% 1.00083-1.02) and 0.02 (HR 
2.54 CI 95% 1.159-5.57).  
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DISCUSSION 
The inflammatory process has a complex role in cancer onset since it could both help 
cancer development, and activate immune response. Several studies have already 
evaluated the role of cytokines in cancer onset, even in HCC. These molecules could be 
divided in Th1 cytokines, that promote the induction of a pro-inflammatory response, 
and Th2 cytokines, which are involved in immune suppression as anti-inflammatory 
molecules. As Th2 anti-inflammatory cytokine IL6 should lead to the shift of Th1/Th2 
balance towards a Th2 response, thus suppressing immunity against cancer and 
promoting cell proliferation. Actually in the literature some authors have reported that 
IL6 promotes cell proliferation via STAT3 activation, while others described IL6 with 
both Th1 and Th2 functions, resulting in a promotion of the inflammatory process and 
of immune surveillance on tumor. As the latter hypothesis describes, in this study IL6 
although without a statistical significance has higher values in cirrhotic patients without 
HCC than in those with cancer, likely suggesting a role in immune surveillance. 
TNF-α exerts its role as pro-inflammatory cytokine by activating NF-κB and the 
resulting cascade of events, with a cytoprotective effect. Instead in case of advanced 
cirrhosis the same events allow neoplastic cells survival through the activation of the 
TNF-α/ROS/HIF-1α induced by FoxM1 overexpression. Thus, TNF-α can both promote 
and counteract cancer onset. 
Although TNF-α was reported at higher concentrationes in HCC patients, in this study 
the data were not consistent to those reported in the litterature 
Adhesion proteins allow the passage of leukocytes from blood to hepatic parenchyma. 
They are obviously more represented in a inflammatory context, while their reduction 
leads to a lower number of tumour infiltrating lymphocytes (TIL), which are 
fundamental for immune surveillance. Indeed, in the literature VAP-1 is reported at 
higher concentrations in inflammatory pathology, while its levels are lower in several 
cancers. 
HCC mainly grows in an inflammatory microenvironment as cirrhosis, thus leading to 
various hypotheses concerning the vascular adhesion molecules. Some authors have 
reported VAP-1 at higher levels in HCC patients compared to those with cirrhosis only, 
while in this study VAP-1 has lower concentrations in HCC patients as the literature 
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describes in case of other cancer types. Thus, it can be assumed that the antitumor effect 
of VAP-1 is more important than its pro-inflammatory function, hypothesizing that 
VAP-1 is primarily involved in immune escape through TIL reduction. 
Similarly to VAP-1, the pathogenic mechanism of ICAM-1 seems to be the loss of 
cancer immunosurveillance but with an opposite trend of the concentration of these two 
molecules in HCC patients. Even if in the literature the level of ICAM-1 is reported to 
be higher in HCC patients and to be negatively correlated with prognosis, in this study 
these data weren’t confirmed. 
The hypothesis to be confirmed in future studies is that, since ICAM-1 is expressed in 
both immune and cancer cells, it is likely that its upregulation in the neoplastic clone 
allows this to hide itself in healthy tissues,  thus leading to the immune escape. 
The literature describes that VCAM-1 has higher levels in several tumors, but its 
carcinogenic role is still unclear. Some authors hypothesize that VCAM-1 is pivotal in 
liver diseases and cirrhosis rather than in HCC. Indeed, its level correlates mainly to the 
stage and aetiology of cirrhosis, as confirmed by this paper, supporting the hypothesis 
that its main role is in the inflammatory process and not in carcinogenesis. 
The analysis of these cytokines and adhesion molecules point out how complicated is 
the interaction between inflammatory and cancerogenic processes. These molecules 
have conflicting roles. They act in response to the microenvironment caused by chronic 
liver damage and cirrhosis, thus stimulating cell cycle progression in response to the 
continuos damage-death-regeneration of cells with a resulting disregulation of cell cycle 
and subsequent selection of neoplastic clones. Moreover, cancer clones are able to take 
advantage of the same molecules, hiding themselves into healthy tissues as suggested 
mainly by the overexpression of ICAM described in the literature. On the other hand, 
they are pivotal for activation and migration of the tumor infiltrating lymphocytes and 
the subsequent host immune response against cancer. 
Looking to the prognostic value of the cytokines and vascular adhesion protein, this 
study didn't found any statistical significance between groups, and also in the literature 
data on the prognostic values of these molecules are still conflicting. Actually, as 
described in this study, only the clinical parameters have a prognostic value.  
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LIMITS AND FUTURE AIMS 
The preliminary results are not conclusive and further studies are needed to clarify the 
intriguing role of cytokines and vascular adhesion protein in carcinogenesis and their 
prognostic value.  
The main limit of this paper is the lack of uniformity of the population studied. The 
different rate of staging subgroups in the various population may have affected the 
statistical analysis. 
A prospective case-control study is the next postdoc research topic. The first endpoint 
will be the homogenization of the population to be studied, thus allowing the evaluation 
of patients by stage (Child-Pough; Meld) and by etiology of cirrhosis (alcoholic, HBV, 
HCV), and furthermore making a comparison between the different categories and 
subgroups. Furthermore, as secondary endpoint, the study will focus on finding potential 
therapeutic targets and the subsequent therapeutic implication. 
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